Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Research Study to Evaluate BLX-0871 in Healthy Adults
Sponsor: Biolexis Therapeutics
Summary
This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance. The main goal is to see if BLX-0871 is safe and well tolerated when given to healthy adults. The study will also measure how the body processes BLX-0871, including how quickly it is absorbed, how long it stays in the blood, and how it is eliminated. Another objective is to see whether food affects the absorption of BLX-0871. It will also look at how the drug affects the body by looking at markers of AMPK activity.
Official title: A Phase 1 Randomized, Double-blind, Placebo-controlled Single-ascending Dose and Multiple-ascending Dose (SAD and MAD) Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Isoform-specific AMPK Activator BLX-0871 in Healthy Adults With a Body Mass Index (BMI) of 20 - 35 kg/m2
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2025-09
Completion Date
2026-05
Last Updated
2025-08-24
Healthy Volunteers
Yes
Conditions
Interventions
BLX-0871
BLX-0871 Single or Multiple doses administered orally as a tablet
Placebo
Participants will receive matching placebo of BLX-0871 for each of the oral cohorts.
Locations (1)
Nucleus Network St Kilda Road
Melbourne, New South Wales, Australia